These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35745835)

  • 1. PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell.
    Zha H; Xu Z; Xu X; Lu X; Shi P; Xiao Y; Tsai HI; Su D; Cheng F; Cheng X; Chen H
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy.
    Xu X; Liu L; Wang H; Li W; Zou Y; Zeng Y; Yang Q; Bai D; Dai D
    ACS Biomater Sci Eng; 2022 Nov; 8(11):4819-4826. PubMed ID: 36206367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
    Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
    Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 cellular nanovesicles carrying rapamycin inhibit alloimmune responses in transplantation.
    Yang M; Xu Z; Yan H; Tsai HI; Su D; Yan F; Lu Q; Feng J; Zeng W; Xi L; Zha H; Ling Y; He C; Wu Y; Xu X; Zheng G; Liu G; Chen H; Cheng F
    Biomater Sci; 2021 Feb; 9(4):1246-1255. PubMed ID: 33367372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer.
    Li J; Zhang D; Liu Z; Wang Y; Li X; Wang Z; Liang G; Yuan X; Li Y; Komorowski AL; Rozen WM; Orlandi A; Takabe K; Franceschini G; Jerusalem G; Wang X
    Ann Transl Med; 2023 Jan; 11(2):83. PubMed ID: 36819490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering Programmed Death Ligand-1/Cytotoxic T-Lymphocyte-Associated Antigen-4 Dual-Targeting Nanovesicles for Immunosuppressive Therapy in Transplantation.
    Xu Z; Tsai HI; Xiao Y; Wu Y; Su D; Yang M; Zha H; Yan F; Liu X; Cheng F; Chen H
    ACS Nano; 2020 Jul; 14(7):7959-7969. PubMed ID: 32515579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy.
    Zhang X; Wang C; Wang J; Hu Q; Langworthy B; Ye Y; Sun W; Lin J; Wang T; Fine J; Cheng H; Dotti G; Huang P; Gu Z
    Adv Mater; 2018 May; 30(22):e1707112. PubMed ID: 29656492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer.
    Luo X; Wang H; Ji D
    Aging (Albany NY); 2021 Jun; 13(13):17177-17189. PubMed ID: 34111025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
    Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
    Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
    Chaurasiya S; Yang A; Kang S; Lu J; Kim SI; Park AK; Sivanandam V; Zhang Z; Woo Y; Warner SG; Fong Y
    Oncoimmunology; 2020; 9(1):1729300. PubMed ID: 32158622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
    Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity.
    Sheybani ND; Witter AR; Thim EA; Yagita H; Bullock TNJ; Price RJ
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
    Cyprian FS; Akhtar S; Gatalica Z; Vranic S
    Bosn J Basic Med Sci; 2019 Aug; 19(3):227-233. PubMed ID: 30915922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
    Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
    Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
    Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
    Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.
    Kagihara JA; Andress M; Diamond JR
    Expert Rev Precis Med Drug Dev; 2020; 5(2):59-65. PubMed ID: 32190733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
    Wang X; Liu Y
    Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression.
    Li C; Qiu S; Jin K; Zheng X; Zhou X; Jin D; Xu B; Jin X
    Cancer Lett; 2021 Dec; 523():43-56. PubMed ID: 34601021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer.
    Zhao P; Xu Y; Ji W; Zhou S; Li L; Qiu L; Qian Z; Wang X; Zhang H
    J Nanobiotechnology; 2021 Jun; 19(1):181. PubMed ID: 34120612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.